No Data
No Data
PDS Biotechnology Says Head, Neck Cancer Therapy Met Main Goal in Mid-Stage Study
PDS Biotechnology (PDSB) said late Thursday its experimental therapy to treat a type of head and neck cancer in combination with Merck's Keytruda met the primary study endpoints in a phase 2 clinical
Express News | PDS Biotech's VERSATILE-002 Phase 2 Clinical Trial Met Primary Study Endpoints
Express News | PDS Biotechnology Corp: Plans to Initiate a Pivotal Clinical Trial in 2024 to Advance Its Lead Program in Advanced Head and Neck Squamous Cell Cancers
Express News | PDS Biotech Versatile-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic Hpv16-Positive Head and Neck Cancer
Express News | HC Wainwright & Co. Reiterates Buy on PDS Biotechnology, Maintains $21 Price Target
Express News | Cantor Fitzgerald Reiterates Overweight on PDS Biotechnology